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Glioblastoma (GBM) remains one 
of the most lethal tumors that patients 
and oncologists face today. Extensive 
microinvasion and the limitations proffered 
by the surrounding normal brain essentially 
impede complete surgical extirpation. 
Challenges are similarly met with the 
employment of standard adjunctive 
therapies (including temozolomide-based 
chemotherapy, radiation therapy, and 
bevacizumab-based immunotherapy), 
as tumors often comprise an especially 
heterogeneous mix of terminally 
differentiated cancer cells and therapy-
resistant GBM stem cells (GSCs). These 
are situated amidst a microenvironment 
containing aberrant vascular cells, tumor-
infiltrating immune cells of various types 
and stromal cells.1 Thus, the successful 
treatment of GBM (which to date has 
been hardly, if ever, achieved) is likely 
to necessitate a rational, multifaceted 
approach targeting malignant cells, GSCs, 
and the tumor vasculature.
One component of such a multi-
modal strategy would be the elicitation 
of antitumor immune responses. Our 
immune system, which has evolved 
under continuous selection to protect us 
against pathogens, also has a major role in 
anticancer surveillance,2 and has recently 
been deployed with increasing rates of 
success for cancer therapy. The most 
successful stories told to date in this field 
include that of sipuleucel-T (Provenge®) 
and Ipilimumab (Yervoy®), which are 
now approved by the US Food and Drug 
administration for the treatment of 
prostate cancer and metastatic melanoma, 
respectively. GBM may also be susceptible 
to immunotherapy, as glial cells have 
physiologic antigen-presenting capacities 
and likewise exhibit some degree of 
immunogenicity. In support of this 
notion, GBMs appear to spend a good deal 
of “energy” to evade the immune system, 
and recent work has uncovered some 
of the secrets underlying this process, 
which involves a subversive shift in T-cell 
homeostasis toward the accumulation 
of immunosuppressive regulatory T 
cells (Tregs).3 Furthermore, previous 
concerns related to the immunological 
privilege of the central nervous system 
(CNS) have been largely alleviated, as T 
cells traffic quite well into and out of the 
brain. Moreover, GBMs generally afford 
the added “access advantage” given by a 
myriad of poorly constructed and vascular 
endothelial growth factor (VEGF)-
elicited vessels, which fail to preserve the 
blood-brain barrier.
We have been studying a rational, 
multi-modal therapeutic approach 
against GBM and have employed 
representative tumor models as an 
added stringency. In particular, we have 
recently employed oncolytic viruses 
“armed” with a cytokine, interleukin-12 
(IL-12), that serves not only to promote a 
T
H
1 immune response, but also to target 
the vascular microenvironment of GBM 
while directly killing tumor-initiating 
GSCs,4 Oncolytic viruses selectively 
replicate within (hence killing) cancer 
cells, but not within their normal 
counterparts, and thus have the potential 
to amplify themselves in situ and spread 
throughout the tumor.5 Oncolytic herpes 
simplex virus (oHSV) is particularly 
well suited for immunovirotherapy 
because of its inherent cytolytic activity 
and its ability to induce antitumor 
immune responses.6 Furthermore, the 
third-generation oHSV G47Δ, which 
is being tested in clinical trials, has the 
capacity to replicate within and hence 
kill human GSCs.7 Immunotherapeutic 
strategies based on oncolytic viruses that 
express immunostimulatory cytokines 
such as granulocyte macrophage colony-
stimulating factor (GM-CSF) have 
already shown efficacy in melanoma 
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we have recently described a new murine model of glioblastoma, generated by the implantation of syngeneic 
glioblastoma stem cells into immunocompetent mice, that recapitulates the salient histopathological and immunological 
features of the human disease. we employed this model to demonstrate the multifaceted activity of an oncolytic herpes 
simplex virus genetically modified to express interleukin-12, G47Δ-IL12.
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patients in the context of a Phase III 
clinical trial (NCT00769704).
To evaluate our immunotherapeutic 
approach in stringent conditions, we 
utilized a new murine model of GBM, 
relying on the orthotopic implantation of 
005 GCSs in syngeneic C57Bl/6 mice.4 
The cancer stem cell origin of GBMs in this 
model is important to properly assess GBM-
targeting interventions. Once implanted 
in the brain, 005 cells form tumors 
that reproduce the microenvironment 
and pathology of human GBMs: they 
are morphologically heterogeneous and 
include multinucleated giant cells as well 
as cells that express stem-cell markers 
(i.e., nestin, prominin), they invade the 
surrounding brain parenchyma, and they 
exhibit extensive angiogenesis resulting 
in an aberrant vasculature.4 In addition, 
these tumors are poorly immunogenic, 
as malignant cells do not express on 
their surface MHC class I molecules, 
CD40 or CD80, and recapitulate the 
immunosuppressive microenvironment 
of human GBMs by promoting the 
accumulation of Tregs.4
The intratumoral administration of an 
IL-12-expressing version of G47Δ (G47Δ-
mIL12) effectively targeted neoplastic 
lesions and their microenvironment 
in a multi-modal fashion (Fig. 1), de 
facto improving the survival of mice 
bearing 005-derived GBMs.4 G47Δ-
mIL12 inhibited neovascularization 
and the expression of VEGF not only in 
005-derived GBMs but also in GBMs 
derived from human GSCs.8 In addition, 
this treatment promoted the secretion 
of chemokine (C-X-C motif) ligand 10 
(CXCL10, best known as IP-10), curbing 
the angiogenic fuel for tumor growth, and 
interferon γ (IFNγ), which invariably 
favored the elicitation of T
H
1 immune 
responses.4 Importantly, G47Δ-mIL12 
counteracted the accumulation of Tregs 
within GBM lesions, a primary goal 
of immunotherapies in general, as this 
favors T cell-mediated antitumor immune 
responses. Of note, the efficacy of G47Δ-
mIL12 was abrogated in T cell-deficient 
(athymic) mice, demonstrating the 
importance of T cells in this therapeutic 
paradigm as well as the benefits of shifting 
the tumor microenvironment toward 
T
H
1 immune responses at the expense 
of Tregs. Interestingly, the survival of 
immunodeficient mice bearing human, 
but not mouse, gliomas was extended as 
a result of the anti-angiogenic activity 
of G47Δ-mIL12.8 The use of oHSV as 
a vehicle for the local delivery of IL-12 
appears to be critical, as systemic delivery of 
IL-12 has proven ineffective at altering the 
tumor microenvironment, while exhibiting 
significant toxicity in clinical trials.9 While 
triggering promising therapeutic responses, 
only 20% of GBM-bearing mice treated 
with G47Δ-mIL12 eventually survived. 
Thus, further improvements to boost 
or prolong the T
H
1 immune response 
promoted by G47Δ-mIL12 are required.
Thanks to a new immunocompetent 
orthotopic model of GSC-driven GBM, we 
demonstrated the multifaceted oncolytic, 
anti-angiogenic, and immunostimulatory 
nature of G47Δ-mIL12 (Fig. 1). Such a 
multidimensional approach is likely to 
be critical for the successful treatment 
of GBM in the context of its complex 
and often uniquely immunosuppressive 
milieu.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were 
disclosed.
Figure  1. Multifaceted antineoplastic activity of an interleukin-12-expressing oncolytic herpes 
simplex virus. G47Δ-mIL12 infects and replicates within malignant cells, including cancer stem 
cells, hence killing them. as G47Δ-mIL12 amplifies and spreads throughout the tumor, it promotes 
the expression and release of interleukin-12 (IL-12), which in turn stimulates the production 
of interferon γ (IFNγ). This leads to the inhibition of angiogenesis upon the upregulation of 
chemokine (C-X-C motif) ligand 10 (CXCL10, best known as IP-10) and the downregulation 
of vascular endothelial growth factor (VeGF). IL-12 also inhibits the immunosuppressive 
functions of regulatory T cells (Tregs) and polarizes antitumor immune responses toward a Th1 
profile dominated by CD8+ T cells. Thus, G47Δ-mIL12 targets both malignant cells and their 
microenvironment while stimulating an antitumor immune response.
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